Bluebird bio has officially opened a facility in Durham, North Carolina, to make the lentiviral vector needed for its investigational…
Mary Chapman
Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Mary Chapman
The Multiple Myeloma Research Foundation (MMRF) has launched the Myeloma Investment Fund in an effort to attract promising biotech…
MYELOMA
It’s Off to the Races for eRace Cancer’s 78-year-old Founder and Multiple Myeloma Survivor
In 2003, Don Wright received a daunting diagnosis of multiple myeloma. But not only has the 78-year-old survived, he has…
To raise awareness of multiple myeloma and efforts to cure it, the International Myeloma Foundation (IMF) is gearing up…
MYELOMA
Multiple Myeloma Research Foundation Makes Changes in Leadership to Advance Precision Medicine
The Multiple Myeloma Research Foundation (MMRF) is growing and adjusting its executive team, with a focus on improving multiple…
Owing to an anonymous $75 million gift, New York University (NYU) Langone Health and its Laura and Isaac…
Thanks to a £10 million donation (about $13,000,000), Imperial College London will establish a center for multiple myeloma research…
In a new agreement, Ayala Pharmaceuticals will work with Novartis on the development and commercialization of AL102,…
The Multiple Myeloma Research Foundation (MMRF) is launching a platform clinical trial aimed at investigating treatments for high-risk multiple…
During a strenuous but spectacular hike, a team including four patients is traversing Nepal’s Khumbu region, encountering some of the…